Synta Pharmaceuticals Announces Results Presented at American Association for Cancer Research Further Elucidate Mechanism by Which Elesclomol Targets Cancer Cell Metabolism

LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented five posters at the American Association for Cancer Research (AACR) 102nd Annual Meeting. Three posters reported results from studies of ganetespib (STA-9090), a novel Hsp90 inhibitor, and two posters reported results from studies of elesclomol.